Research site

Dresden, Saxony 1307

2 studies enrolling now · 15 studies all time

What they study most

Asthma, COPD, Chronic Obstructive Pulmonary Disease, Hepatobiliary Cancers, Hypophosphatasia (HPP), Multiple Sclerosis, Opioid-Induced Constipation (OIC), Relapsing Remitting Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis (RRMS), Rheumatoid Arthritis, Secondary Progressive Multiple Sclerosis

Studies at this site

• Observational Study Protocol: LIVER-R — Recruiting now
• Registry of Patients With Hypophosphatasia — Enrolling by invitation
• Observational Study of Obstructive Lung Disease (NOVELTY) — Completed
• Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS) — Completed
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) — Stopped early
• Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS — Completed
• Study of BIIB092 in Participants With Progressive Supranuclear Palsy — Stopped early
• PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis — Completed
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 — Stopped early
• Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab — Stopped early
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis — Stopped early
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis — Completed
• Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation — Completed
• Treatment Interruption of Natalizumab — Completed
• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD — Completed